X0306 4 2021-02-22 0 0001682852 Moderna, Inc. MRNA 0001222012 AFEYAN NOUBAR 55 CAMBRIDGE PARKWAY, SUITE 800E CAMBRIDGE MA 02142 1 0 0 0 Common Stock 2021-02-22 4 S 0 161887 159.1794 D 19245278 I By Flagship Ventures Fund IV, L.P. and Flagship Ventures Fund IV-Rx, L.P. Common Stock 2021-02-22 4 S 0 54409 160.3709 D 19190869 I By Flagship Ventures Fund IV, L.P. and Flagship Ventures Fund IV-Rx, L.P. Common Stock 2021-02-22 4 S 0 30808 160.9585 D 19160061 I By Flagship Ventures Fund IV, L.P. and Flagship Ventures Fund IV-Rx, L.P. Common Stock 2021-02-22 4 S 0 250501 162.3628 D 18909560 I By Flagship Ventures Fund IV, L.P. and Flagship Ventures Fund IV-Rx, L.P. Common Stock 2021-02-22 4 S 0 366471 163.2527 D 18543089 I By Flagship Ventures Fund IV, L.P. and Flagship Ventures Fund IV-Rx, L.P. Common Stock 2021-02-22 4 S 0 189200 164.1346 D 18353889 I By Flagship Ventures Fund IV, L.P. and Flagship Ventures Fund IV-Rx, L.P. Common Stock 2021-02-22 4 S 0 165578 165.4687 D 18188311 I By Flagship Ventures Fund IV, L.P. and Flagship Ventures Fund IV-Rx, L.P. Common Stock 2021-02-22 4 S 0 351578 166.2968 D 17837101 I By Flagship Ventures Fund IV, L.P. and Flagship Ventures Fund IV-Rx, L.P. Common Stock 2021-02-22 4 S 0 122715 167.1006 D 17714386 I By Flagship Ventures Fund IV, L.P. and Flagship Ventures Fund IV-Rx, L.P. Common Stock 2021-02-22 4 S 0 58377 168.1117 D 17656009 I By Flagship Ventures Fund IV, L.P. and Flagship Ventures Fund IV-Rx, L.P. Common Stock 2021-02-22 4 S 0 54274 169.1401 D 17601735 I By Flagship Ventures Fund IV, L.P. and Flagship Ventures Fund IV-Rx, L.P. Common Stock 2021-02-22 4 S 0 30968 170.0278 D 17570797 I By Flagship Ventures Fund IV, L.P. and Flagship Ventures Fund IV-Rx, L.P. Common Stock 2021-02-23 4 S 0 9985 136.482 D 17560812 I By Flagship Ventures Fund IV, L.P. and Flagship Ventures Fund IV-Rx, L.P. Common Stock 2021-02-23 4 S 0 122142 137.2906 D 17438670 I By Flagship Ventures Fund IV, L.P. and Flagship Ventures Fund IV-Rx, L.P. Common Stock 2021-02-23 4 S 0 46222 138.5585 D 17392448 I By Flagship Ventures Fund IV, L.P. and Flagship Ventures Fund IV-Rx, L.P. Common Stock 2021-02-23 4 S 0 56435 139.6447 D 17336013 I By Flagship Ventures Fund IV, L.P. and Flagship Ventures Fund IV-Rx, L.P. Common Stock 2021-02-23 4 S 0 102852 140.236 D 17233161 I By Flagship Ventures Fund IV, L.P. and Flagship Ventures Fund IV-Rx, L.P. Common Stock 2021-02-23 4 S 0 70631 141.4573 D 17162530 I By Flagship Ventures Fund IV, L.P. and Flagship Ventures Fund IV-Rx, L.P. Common Stock 2021-02-23 4 S 0 117011 142.7605 D 17045519 I By Flagship Ventures Fund IV, L.P. and Flagship Ventures Fund IV-Rx, L.P. Common Stock 2021-02-23 4 S 0 397126 143.5744 D 16648393 I By Flagship Ventures Fund IV, L.P. and Flagship Ventures Fund IV-Rx, L.P. Common Stock 2021-02-23 4 S 0 405551 144.5529 D 16242842 I By Flagship Ventures Fund IV, L.P. and Flagship Ventures Fund IV-Rx, L.P. Common Stock 2021-02-23 4 S 0 357316 145.4803 D 15885526 I By Flagship Ventures Fund IV, L.P. and Flagship Ventures Fund IV-Rx, L.P. Common Stock 2021-02-23 4 S 0 307795 146.6369 D 15577731 I By Flagship Ventures Fund IV, L.P. and Flagship Ventures Fund IV-Rx, L.P. Common Stock 2021-02-23 4 S 0 292483 147.5729 D 15285248 I By Flagship Ventures Fund IV, L.P. and Flagship Ventures Fund IV-Rx, L.P. Common Stock 2021-02-23 4 S 0 268688 148.521 D 15016560 I By Flagship Ventures Fund IV, L.P. and Flagship Ventures Fund IV-Rx, L.P. Common Stock 2021-02-23 4 S 0 179268 149.626 D 14837292 I By Flagship Ventures Fund IV, L.P. and Flagship Ventures Fund IV-Rx, L.P. Common Stock 2021-02-23 4 S 0 190710 150.5137 D 14646582 I By Flagship Ventures Fund IV, L.P. and Flagship Ventures Fund IV-Rx, L.P. Common Stock 2021-02-23 4 S 0 23423 151.2851 D 14623159 I By Flagship Ventures Fund IV, L.P. and Flagship Ventures Fund IV-Rx, L.P. Common Stock 11464359 I By Flagship VentureLabs IV LLC and Flagship Pioneering, Inc. Common Stock 2101703 D These sales were effected by Flagship Ventures Fund IV, L.P. ("Flagship Fund IV") and Flagship Ventures Fund IV-Rx, L.P. ("Flagship Fund IV-Rx") pursuant to Rule 10b5-1 trading plans adopted on December 23, 2020. Represents 135,986 shares sold by Flagship Fund IV and 25,901 shares sold by Flagship Fund IV-Rx. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $158.65 to $159.61, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Shares held directly by Flagship Fund IV and Flagship Fund IV-Rx. Flagship Ventures Fund IV General Partner LLC ("Flagship Fund IV GP") is the general partner of each of Flagship Fund IV and Flagship Fund IV-Rx. The reporting person is the sole manager of Flagship Fund IV GP and disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein. Represents 45,703 shares sold by Flagship Fund IV and 8,706 shares sold by Flagship Fund IV-Rx. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $159.65 to $160.64, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Represents 25,879 shares sold by Flagship Fund IV and 4,929 shares sold by Flagship Fund IV-Rx. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $160.65 to $161.54, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Represents 210,421 shares sold by Flagship Fund IV and 40,080 shares sold by Flagship Fund IV-Rx. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $161.79 to $162.78, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Represents 307,835 shares sold by Flagship Fund IV and 58,636 shares sold by Flagship Fund IV-Rx. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $162.79 to $163.78, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Represents 158,928 shares sold by Flagship Fund IV and 30,272 shares sold by Flagship Fund IV-Rx. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $163.79 to $164.78, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Represents 139,086 shares sold by Flagship Fund IV and 26,492 shares sold by Flagship Fund IV-Rx. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $164.79 to $165.78, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Represents 295,016 shares sold by Flagship Fund IV and 56,194 shares sold by Flagship Fund IV-Rx. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $165.79 to $166.78, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Represents 103,081 shares sold by Flagship Fund IV and 19,634 shares sold by Flagship Fund IV-Rx. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $166.79 to $167.78, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Represents 49,037 shares sold by Flagship Fund IV and 9,340 shares sold by Flagship Fund IV-Rx. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $167.79 to $168.75, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Represents 45,589 shares sold by Flagship Fund IV and 8,685 shares sold by Flagship Fund IV-Rx. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $168.80 to $169.79, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Represents 25,989 shares sold by Flagship Fund IV and 4,949 shares sold by Flagship Fund IV-Rx. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $169.85 to $170.35, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Represents 8,387 shares sold by Flagship Fund IV and 1,598 shares sold by Flagship Fund IV-Rx. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $136.01 to $137.00, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Represents 102,600 shares sold by Flagship Fund IV and 19,542 shares sold by Flagship Fund IV-Rx. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $137.01 to $137.96, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Represents 38,826 shares sold by Flagship Fund IV and 7,396 shares sold by Flagship Fund IV-Rx. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $138.03 to $139.01, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Represents 47,406 shares sold by Flagship Fund IV and 9,029 shares sold by Flagship Fund IV-Rx. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $139.05 to $140.04, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Represents 86,395 shares sold by Flagship Fund IV and 16,457 shares sold by Flagship Fund IV-Rx. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $140.05 to $140.92, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Represents 59,330 shares sold by Flagship Fund IV and 11,301 shares sold by Flagship Fund IV-Rx. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $141.06 to $142.05, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Represents 98,290 shares sold by Flagship Fund IV and 18,721 shares sold by Flagship Fund IV-Rx. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $142.06 to $143.05, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Represents 333,586 shares sold by Flagship Fund IV and 63,540 shares sold by Flagship Fund IV-Rx. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $143.06 to $144.05, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Represents 340,662 shares sold by Flagship Fund IV and 64,889 shares sold by Flagship Fund IV-Rx. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $144.06 to $145.05, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Represents 300,146 shares sold by Flagship Fund IV and 57,170 shares sold by Flagship Fund IV-Rx. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $145.06 to $146.05, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Represents 258,547 shares sold by Flagship Fund IV and 49,248 shares sold by Flagship Fund IV-Rx. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $146.07 to $147.06, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Represents 245,686 shares sold by Flagship Fund IV and 46,797 shares sold by Flagship Fund IV-Rx. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $147.07 to $148.06, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Represents 225,698 shares sold by Flagship Fund IV and 42,990 shares sold by Flagship Fund IV-Rx. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $148.07 to $149.06, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Represents 150,585 shares sold by Flagship Fund IV and 28,683 shares sold by Flagship Fund IV-Rx. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $149.07 to $150.06, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Represents 160,196 shares sold by Flagship Fund IV and 30,514 shares sold by Flagship Fund IV-Rx. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $150.08 to $151.07, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Represents 19,676 shares sold by Flagship Fund IV and 3,747 shares sold by Flagship Fund IV-Rx. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $151.08 to $151.64, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Following the transactions reported herein, 10,417,023 shares are held directly by Flagship Fund IV and 4,206,136 shares are held directly by Flagship Fund IV-Rx. 11,460,435 shares are held directly by Flagship VentureLabs IV LLC ("VentureLabs IV") and 3,924 shares are held directly by Flagship Pioneering, Inc. ("Flagship Pioneering"). Flagship Fund IV is a member of VentureLabs IV and also serves as its manager. Flagship Fund IV GP is the general partner of Flagship Fund IV. The reporting person is the sole manager of Flagship Fund IV GP and CEO and sole stockholder of Flagship Pioneering and disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein. Noubar B. Afeyan, Ph.D. By: /s/ Noubar B. Afeyan, Ph.D. 2021-02-24